Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Noetik Enters $50M AI Collaboration with GSK, Licensing OCTO‑VC Virtual Cell Models for NSCLC and CRC

Fineline Cube Jan 12, 2026
Company Deals

Mirxes Partners with Thailand’s N Health to Launch miRNA Cancer Screening

Fineline Cube Jan 12, 2026
Company Deals

Biocytogen Licenses ADC Programs to Acepodia in Option Deal

Fineline Cube Jan 12, 2026
Company Deals

Simcere Pharma to Spin Off Zaiming Unit for Hong Kong IPO

Fineline Cube Jan 12, 2026
Company Deals

Nona Biosciences Partners with Link Cell on CAR-T Discovery Using HCAb Platform

Fineline Cube Jan 12, 2026
Company Drug Policy / Regulatory

FDA Announces Flexible CMC Pathway for Cell and Gene Therapies to Accelerate Development

Fineline Cube Jan 12, 2026
Company Drug

Alphamab Oncology Submits Envafolimab for First‑Line Biliary Tract Cancer (BTC) as World’s First Subcutaneous PD‑L1

Fineline Cube Jan 12, 2026
Company Drug

Pfizer’s BRAFTOVI Trio Achieves 64 % Response Rate in BREAKWATER Cohort 3 for BRAF V600E Metastatic Colorectal Cancer

Fineline Cube Jan 12, 2026
Company Drug

Grand Pharma’s TLX591-CDx Approved for Prostate Cancer Diagnosis in China

Fineline Cube Oct 18, 2022

China-based Grand Pharmaceutical Group Limited (HKG: 0512) has announced that its Investigational New Drug (IND)...

Company Deals

Kunshi Biotechnology Raises Angel Funding for Engineered Macrophage Platform

Fineline Cube Oct 17, 2022

China-based Kunshi Biotechnology (Shenzhen) Co., Ltd, a company specializing in gene editing, biomaterials, and synthetic...

Company Drug

Akeso Biopharma’s Cadonilimab Recommended as First-Line Treatment for Cervical Cancer

Fineline Cube Oct 17, 2022

China-based biotech Akeso Biopharma (HKG: 9926) has revealed that its cadonilimab (AK104) has been included...

Company Drug

Fosun Kite’s Yescarta Gains Priority Review Status for r/r LBCL

Fineline Cube Oct 17, 2022

China-based Fosun Kite Biotechnology Co., Ltd, a joint venture (JV) between Shanghai Fosun Pharmaceutical (Group)...

Company Drug

Genor Biopharma Initiates First Patient Dosing for GB263T in China

Fineline Cube Oct 17, 2022

China’s Genor Biopharma Co., Ltd (HKG: 6998) has announced the first patient dosing in a...

Company Drug

Akeso Biopharma Gains NMPA Approval for AK112 and AK119 Clinical Study

Fineline Cube Oct 17, 2022

China-based Akeso Biopharma (HKG: 9926) has announced receiving approval from the National Medical Products Administration...

Company Drug

Innovent Biologics Publishes Mazdutide Phase Ib Study Results for Obesity

Fineline Cube Oct 17, 2022

China-based Innovent Biologics, Inc. (HKG: 1801) has announced that the results of the higher-dose cohorts...

Company Deals

Sihuan Pharma to Acquire Additional Stake in Heilongjiang Duoduo Pharma

Fineline Cube Oct 17, 2022

China-based Sihuan Pharmaceutical Holdings Group Ltd’s subsidiary, Beijing Centergate Technologies (Holding) Co., Ltd (SHE: 000931),...

Policy / Regulatory

NHSA Completes Expert Review for NRDL Price Negotiation Process

Fineline Cube Oct 17, 2022

The National Healthcare Security Administration (NHSA) has released a notification indicating that the expert review...

Company Drug

BeiGene’s Brukinsa Receives Positive CHMP Opinion for CLL Approval

Fineline Cube Oct 17, 2022

China-based biotech BeiGene Inc. (HKG: 6160, SHA: 688235, NASDAQ: BGNE) has announced receiving a positive opinion...

Company Drug

Kira Pharmaceuticals Gains NMPA Approval for Phase II Study of KP104 in PNH

Fineline Cube Oct 17, 2022

Sino-US biotech Kira Pharmaceuticals has announced receiving approval from the National Medical Products Administration (NMPA)...

Company Drug

RemeGen’s Telitacicept Gains EU, China Approvals for Global Phase III Study

Fineline Cube Oct 17, 2022

China-based pharma firm RemeGen (HKG: 9995) has announced receiving approvals from authorities in the European...

Company Drug

Zelgen’s Jacktinib Shows Strong Efficacy in Phase III Myelofibrosis Study

Fineline Cube Oct 17, 2022

Suzhou Zelgen Biopharmaceuticals Co., Ltd (SHA: 688266) has published major data from a Phase III...

Company Deals

Ningbo Menovo to Sell Zhejiang Liaoyuan Pharma Stake to Jemincare for RMB 512.58M

Fineline Cube Oct 17, 2022

China-based Ningbo Menovo Pharmaceutical Co., Ltd (SHA: 603538) has announced plans to transfer all of...

Company Deals

Ausper Biopharma Raises USD 16M for HBV Drug and Vaccine Development

Fineline Cube Oct 14, 2022

Ausper Biopharma, Inc, a developer of drugs and vaccines for chronic hepatitis B virus (HBV)...

Company Deals

Alioth Biotech Raises RMB 100M in Series A Financing for Pharma Processing Products

Fineline Cube Oct 14, 2022

China-based Alioth Biotech (Shanghai) Co., Ltd has raised close to RMB 100 million (USD 13.9...

Company Deals

HICOMP MicroTech Raises RMB 100M in Series B+ Financing for Microfluidics Expansion

Fineline Cube Oct 14, 2022

China-based micro/nano technology developer HICOMP MicroTech (Suzhou) Co., Ltd has raised RMB 100 million (USD...

Company Drug

Kintor’s Dual c-Myc/GSPT1 Degradation Therapy GT19715 Shows Promise in Pre-Clinical Studies

Fineline Cube Oct 14, 2022

China-based Kintor Pharmaceutical Ltd (HKG: 9939) has published positive results from a pre-clinical study of...

Company Drug

CARsgen’s BCMA-Targeted CAR-T Therapy CT053 Gains Priority Review in China

Fineline Cube Oct 14, 2022

The Center for Drug Evaluation (CDE) website indicates that China-based chimeric antigen receptor (CAR)-T cell...

Company Drug

LianBio Cancels Phase III Trial for Truseltiq in China Amid Global Halt

Fineline Cube Oct 14, 2022

China-based LianBio (OTCMKTS: LIANY) revealed in an SEC filing that it is canceling work on...

Posts pagination

1 … 556 557 558 … 607

Recent updates

  • Noetik Enters $50M AI Collaboration with GSK, Licensing OCTO‑VC Virtual Cell Models for NSCLC and CRC
  • Alphamab Oncology Submits Envafolimab for First‑Line Biliary Tract Cancer (BTC) as World’s First Subcutaneous PD‑L1
  • Pfizer’s BRAFTOVI Trio Achieves 64 % Response Rate in BREAKWATER Cohort 3 for BRAF V600E Metastatic Colorectal Cancer
  • Insilico Medicine Doses First Patient in Phase IIa Study of AI‑Designed ISM5411 for Inflammatory Bowel Disease
  • Lynk Pharmaceuticals Reports Positive Phase III Data for Zemprocitinib in Rheumatoid Arthritis – Best‑in‑Class JAK1 Inhibitor Shows 79 % ACR20 Response
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Deals

Noetik Enters $50M AI Collaboration with GSK, Licensing OCTO‑VC Virtual Cell Models for NSCLC and CRC

Company Drug

Alphamab Oncology Submits Envafolimab for First‑Line Biliary Tract Cancer (BTC) as World’s First Subcutaneous PD‑L1

Company Drug

Pfizer’s BRAFTOVI Trio Achieves 64 % Response Rate in BREAKWATER Cohort 3 for BRAF V600E Metastatic Colorectal Cancer

Company Drug

Insilico Medicine Doses First Patient in Phase IIa Study of AI‑Designed ISM5411 for Inflammatory Bowel Disease

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.